| Risks, benefits, and issues in creating a behind-the-counter category of medications. | |
| | |
MedLine Citation:
|
PMID: 21247824 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Objective: To examine the issues surrounding the development and implementation of a behind-the-counter (BTC) category of medications.Data sources: Testimony from organizations submitting comments to the Food and Drug Administration (FDA) panel hearings in November 2007, the 2009 final report of the U. S. General Accounting Office regarding a BTC drug category, literature review of research that has been conducted, experiences from other countries, and publically available information from agencies in charge of regulating medications similar to BTC.Summary: Based on evidence attained from the current work, the following six recommendations regarding a BTC category of medications are provided. (1) Demonstration needs to occur that the risks and/or costs of BTC are outweighed by benefits, positive measurable outcomes, and financial savings to society. (2) Sufficient resources, including personnel, equipment, and facilities, need to be available for the appropriate provision of BTC services and to ensure ongoing monitoring and controls. (3) An appropriate compensation structure needs to be developed. (4) Encounters and outcomes should be documented in an electronic record, the information should be shared with other health care providers involved in patients' care, and interprofessional collaboration and communication should occur. (5) Criteria for designating candidates for transition, ongoing review for safety, and reverse transition must be developed. (6) Applicable lessons learned from other countries should be incorporated into BTC strategies. In addition to implementation recommendations, we also summarize additional evidence that needs to be gathered to optimize the BTC model.Conclusion: Based on the accumulated evidence, comments to FDA's request, and information from other countries, implementation of a BTC model probably is feasible in the United States. However, the optimal model remains uncertain and various aspects of a program need to be prioritized and rigorously tested. |
| | |
Authors:
|
L Douglas Ried; Sally A Huston; Suzan N Kucukarslan; Elliott M Sogol; Kenneth W Schafermeyer; Sujit S Sansgiry |
Related Documents
:
|
16610714 - Drive systems for miniature pumps. 10179574 - Idis-ks: an intelligent drug information system as a knowledge server. 15460804 - Medical information systems for cardiac risk assessment and remote monitoring. 17282494 - Bioenergy based medical diagnostic application based on gas discharge visualization. 11298254 - Randomized trial of psychotropic medication information leaflets for people with intell... 8870434 - Outbreak of contact dermatitis related to acticide ep paste in a paint manufacturing fa... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of the American Pharmacists Association : JAPhA Volume: 51 ISSN: 1544-3450 ISO Abbreviation: J Am Pharm Assoc (2003) Publication Date: 2011 Jan-Feb |
Date Detail:
|
Created Date: 2011-01-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101176252 Medline TA: J Am Pharm Assoc (2003) Country: United States |
Other Details:
|
Languages: eng Pagination: 26-39 Citation Subset: IM |
Affiliation:
|
College of Pharmacy, Southwestern Oklahoma State University, Weatherford. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of ...
Next Document: Clinical and economic outcomes of a pilot project examining pharmacist-focused collaborative care tr...